HBsAg
Assets acting on this target.
- Class
- HBsAg-neutralizing monoclonal antibody
By indication
Related mechanisms
HBsAg drugs compared
4 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Hepatitis B immune globulin (HepaGam B)HepaGam B | Kamada | plasma fraction (hepatitis B immunoglobulin) | Approved | Approved in Chronic Hepatitis B |
| Hepatitis B immune globulin (I.V.-Hepabig) | GC Biopharma Corp. | polyclonal antibody (human hepatitis B immunoglobulin) | Phase 3 | Phase 3 in Chronic Hepatitis B |
| Tobevibart (VIR-3434) | Brii Biosciences, Norgine, Vir Biotechnology | monoclonal antibody | Phase 3 | Phase 3 in Chronic Hepatitis Delta |
| ACT201 | Xiamen Amoytop Biotech Co., Ltd. | antisense oligonucleotide | Phase 1 | Phase 1 in Chronic Hepatitis B |